Osteogenic Osteosarcoma

Jianning Tao, Yangjin Bae, Lisa L. Wang, Brendan Lee

Research output: Chapter in Book/Report/Conference proceedingChapter

3 Citations (Scopus)

Abstract

Recent reviews on studies of familial syndromes, specimens, and cell lines derived from human osteosarcoma patients describe the genetic factors and signaling pathways that may be involved in several key processes in the pathogenesis, including initiation, progression, invasion, and metastasis. This chapter updates the current understanding of osteogenic osteosarcoma biology and reviews these recent findings from animal models. Osteosarcoma premalignant cells that initially acquire a mutation in different stages of osteoblast differentiation may transform or evolve into cancer stem cells (CSCs) or tumor initiating cells (TICs) through accumulation of additional genetic mutations during the tumor progression. The current challenge in application of targeted agents lies in the identification of biomarkers predictive of response/resistance and matching them with the particular histologic response of individual patients, hopefully resulting in successful translation of biology into clinical benefit.

Original languageEnglish (US)
Title of host publicationPrimer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism
Subtitle of host publicationEighth Edition
PublisherWiley-Blackwell
Pages702-710
Number of pages9
ISBN (Electronic)9781118453926
ISBN (Print)9781118453889
DOIs
StatePublished - Jul 19 2013

Fingerprint

Osteosarcoma
Tumors
Neoplastic Stem Cells
Osteoblasts
Biomarkers
Stem cells
Mutation
Animals
Cells
Animal Models
Neoplasm Metastasis
Cell Line
Neoplasms

Keywords

  • Animal models
  • Biomarkers
  • Cancer stem cells (CSCs)
  • Mutations
  • Osteogenic osteosarcoma

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Tao, J., Bae, Y., Wang, L. L., & Lee, B. (2013). Osteogenic Osteosarcoma. In Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism: Eighth Edition (pp. 702-710). Wiley-Blackwell. https://doi.org/10.1002/9781118453926.ch85

Osteogenic Osteosarcoma. / Tao, Jianning; Bae, Yangjin; Wang, Lisa L.; Lee, Brendan.

Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism: Eighth Edition. Wiley-Blackwell, 2013. p. 702-710.

Research output: Chapter in Book/Report/Conference proceedingChapter

Tao, J, Bae, Y, Wang, LL & Lee, B 2013, Osteogenic Osteosarcoma. in Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism: Eighth Edition. Wiley-Blackwell, pp. 702-710. https://doi.org/10.1002/9781118453926.ch85
Tao J, Bae Y, Wang LL, Lee B. Osteogenic Osteosarcoma. In Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism: Eighth Edition. Wiley-Blackwell. 2013. p. 702-710 https://doi.org/10.1002/9781118453926.ch85
Tao, Jianning ; Bae, Yangjin ; Wang, Lisa L. ; Lee, Brendan. / Osteogenic Osteosarcoma. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism: Eighth Edition. Wiley-Blackwell, 2013. pp. 702-710
@inbook{abab48596fcd40de98900f55f56969f9,
title = "Osteogenic Osteosarcoma",
abstract = "Recent reviews on studies of familial syndromes, specimens, and cell lines derived from human osteosarcoma patients describe the genetic factors and signaling pathways that may be involved in several key processes in the pathogenesis, including initiation, progression, invasion, and metastasis. This chapter updates the current understanding of osteogenic osteosarcoma biology and reviews these recent findings from animal models. Osteosarcoma premalignant cells that initially acquire a mutation in different stages of osteoblast differentiation may transform or evolve into cancer stem cells (CSCs) or tumor initiating cells (TICs) through accumulation of additional genetic mutations during the tumor progression. The current challenge in application of targeted agents lies in the identification of biomarkers predictive of response/resistance and matching them with the particular histologic response of individual patients, hopefully resulting in successful translation of biology into clinical benefit.",
keywords = "Animal models, Biomarkers, Cancer stem cells (CSCs), Mutations, Osteogenic osteosarcoma",
author = "Jianning Tao and Yangjin Bae and Wang, {Lisa L.} and Brendan Lee",
year = "2013",
month = "7",
day = "19",
doi = "10.1002/9781118453926.ch85",
language = "English (US)",
isbn = "9781118453889",
pages = "702--710",
booktitle = "Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism",
publisher = "Wiley-Blackwell",
address = "United States",

}

TY - CHAP

T1 - Osteogenic Osteosarcoma

AU - Tao, Jianning

AU - Bae, Yangjin

AU - Wang, Lisa L.

AU - Lee, Brendan

PY - 2013/7/19

Y1 - 2013/7/19

N2 - Recent reviews on studies of familial syndromes, specimens, and cell lines derived from human osteosarcoma patients describe the genetic factors and signaling pathways that may be involved in several key processes in the pathogenesis, including initiation, progression, invasion, and metastasis. This chapter updates the current understanding of osteogenic osteosarcoma biology and reviews these recent findings from animal models. Osteosarcoma premalignant cells that initially acquire a mutation in different stages of osteoblast differentiation may transform or evolve into cancer stem cells (CSCs) or tumor initiating cells (TICs) through accumulation of additional genetic mutations during the tumor progression. The current challenge in application of targeted agents lies in the identification of biomarkers predictive of response/resistance and matching them with the particular histologic response of individual patients, hopefully resulting in successful translation of biology into clinical benefit.

AB - Recent reviews on studies of familial syndromes, specimens, and cell lines derived from human osteosarcoma patients describe the genetic factors and signaling pathways that may be involved in several key processes in the pathogenesis, including initiation, progression, invasion, and metastasis. This chapter updates the current understanding of osteogenic osteosarcoma biology and reviews these recent findings from animal models. Osteosarcoma premalignant cells that initially acquire a mutation in different stages of osteoblast differentiation may transform or evolve into cancer stem cells (CSCs) or tumor initiating cells (TICs) through accumulation of additional genetic mutations during the tumor progression. The current challenge in application of targeted agents lies in the identification of biomarkers predictive of response/resistance and matching them with the particular histologic response of individual patients, hopefully resulting in successful translation of biology into clinical benefit.

KW - Animal models

KW - Biomarkers

KW - Cancer stem cells (CSCs)

KW - Mutations

KW - Osteogenic osteosarcoma

UR - http://www.scopus.com/inward/record.url?scp=85018601209&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018601209&partnerID=8YFLogxK

U2 - 10.1002/9781118453926.ch85

DO - 10.1002/9781118453926.ch85

M3 - Chapter

AN - SCOPUS:85018601209

SN - 9781118453889

SP - 702

EP - 710

BT - Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism

PB - Wiley-Blackwell

ER -